yteaaron88
2021-07-20
Like
BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum<blockquote>BioNTech 从吉利德手中收购实体瘤 TCR 平台和生产基地，金额未公开</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":171169659,"tweetId":"171169659","gmtCreate":1626715558271,"gmtModify":1631888932669,"author":{"id":3586955264029856,"idStr":"3586955264029856","authorId":3586955264029856,"authorIdStr":"3586955264029856","name":"yteaaron88","avatar":"https://static.tigerbbs.com/b5a9adeb4d55b3f87731ddb20a7b5fba","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Like </p></body></html>","htmlText":"<html><head></head><body><p>Like </p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/171169659","repostId":1160801924,"repostType":4,"repost":{"id":"1160801924","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1626709874,"share":"https://www.laohunote.com/m/news/1160801924?lang=zh_CN&edition=full","pubTime":"2021-07-19 23:51","market":"us","language":"en","title":"BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum<blockquote>BioNTech 从吉利德手中收购实体瘤 TCR 平台和生产基地，金额未公开</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1160801924","media":"Benzinga Earnings","summary":"BioNTech SE is buying a cell therapy R&D platform plus a manufacturing site from Gilead Science Inc'","content":"<p><b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> is buying a cell therapy R&D platform plus a manufacturing site from <b>Gilead Science Inc's</b>GILD 0.91%Kite subsidiary.</p><p><blockquote><b><a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a></b>正在购买细胞治疗研发平台和生产基地<b>吉利德科学公司</b>GILD 0.91%Kite 子公司。</blockquote></p><p> The deal gives BioNTech Kite's R&D IP for its personalized solid tumor neoantigen T cell receptor (TCR) work and the manufacturing center in Gaithersburg, MD, which supplies the clinical trial product.</p><p><blockquote>该交易为 BioNTech Kite 提供了其个性化实体瘤新抗原 T 细胞受体 (TCR) 工作的研发知识产权，以及供应临床试验产品的马里兰州盖瑟斯堡制造中心。</blockquote></p><p> This program builds and further extends BioNTech's leadership in individualized neoantigen targeting programs such as BNT122 (iNeST) and BNT221 (NEOSTIM).</p><p><blockquote>该计划建立并进一步扩展了 BioNTech 在个体化新抗原靶向计划（如 BNT122 (iNeST) 和 BNT221 (NEOSTIM)）方面的领导地位。</blockquote></p><p> The acquired Gaithersburg facility will provide production capacity to support clinical trials in the U.S. and complement BioNTech's existing cell therapy manufacturing facility in Germany.</p><p><blockquote>收购的盖瑟斯堡工厂将提供产能以支持美国的临床试验，并补充 BioNTech 现有的德国细胞疗法制造工厂。</blockquote></p><p> Financial terms were not disclosed.</p><p><blockquote>财务条款没有披露。</blockquote></p><p> Kite's new manufacturing facility in Frederick, MD, for commercial production of CAR T-cell therapy is not part of the purchase agreement.</p><p><blockquote>Kite 位于马里兰州弗雷德里克的新制造工厂用于 CAR T 细胞疗法的商业生产，不在购买协议的一部分。</blockquote></p><p> <b>Price Action:</b> BNTX shares are up 0.86% at $233.46 during the market session on the last check Monday.</p><p><blockquote><b>价格行为：</b>周一最后一次检查的市场交易中，BNTX 股价上涨 0.86%，至 233.46 美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum<blockquote>BioNTech 从吉利德手中收购实体瘤 TCR 平台和生产基地，金额未公开</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum<blockquote>BioNTech 从吉利德手中收购实体瘤 TCR 平台和生产基地，金额未公开</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-07-19 23:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> is buying a cell therapy R&D platform plus a manufacturing site from <b>Gilead Science Inc's</b>GILD 0.91%Kite subsidiary.</p><p><blockquote><b><a href=\"https://laohu8.com/S/BNTX\">生物科技公司</a></b>正在购买细胞治疗研发平台和生产基地<b>吉利德科学公司</b>GILD 0.91%Kite 子公司。</blockquote></p><p> The deal gives BioNTech Kite's R&D IP for its personalized solid tumor neoantigen T cell receptor (TCR) work and the manufacturing center in Gaithersburg, MD, which supplies the clinical trial product.</p><p><blockquote>该交易为 BioNTech Kite 提供了其个性化实体瘤新抗原 T 细胞受体 (TCR) 工作的研发知识产权，以及供应临床试验产品的马里兰州盖瑟斯堡制造中心。</blockquote></p><p> This program builds and further extends BioNTech's leadership in individualized neoantigen targeting programs such as BNT122 (iNeST) and BNT221 (NEOSTIM).</p><p><blockquote>该计划建立并进一步扩展了 BioNTech 在个体化新抗原靶向计划（如 BNT122 (iNeST) 和 BNT221 (NEOSTIM)）方面的领导地位。</blockquote></p><p> The acquired Gaithersburg facility will provide production capacity to support clinical trials in the U.S. and complement BioNTech's existing cell therapy manufacturing facility in Germany.</p><p><blockquote>收购的盖瑟斯堡工厂将提供产能以支持美国的临床试验，并补充 BioNTech 现有的德国细胞疗法制造工厂。</blockquote></p><p> Financial terms were not disclosed.</p><p><blockquote>财务条款没有披露。</blockquote></p><p> Kite's new manufacturing facility in Frederick, MD, for commercial production of CAR T-cell therapy is not part of the purchase agreement.</p><p><blockquote>Kite 位于马里兰州弗雷德里克的新制造工厂用于 CAR T 细胞疗法的商业生产，不在购买协议的一部分。</blockquote></p><p> <b>Price Action:</b> BNTX shares are up 0.86% at $233.46 during the market session on the last check Monday.</p><p><blockquote><b>价格行为：</b>周一最后一次检查的市场交易中，BNTX 股价上涨 0.86%，至 233.46 美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160801924","content_text":"BioNTech SE is buying a cell therapy R&D platform plus a manufacturing site from Gilead Science Inc'sGILD 0.91%Kite subsidiary.\nThe deal gives BioNTech Kite's R&D IP for its personalized solid tumor neoantigen T cell receptor (TCR) work and the manufacturing center in Gaithersburg, MD, which supplies the clinical trial product.\nThis program builds and further extends BioNTech's leadership in individualized neoantigen targeting programs such as BNT122 (iNeST) and BNT221 (NEOSTIM).\nThe acquired Gaithersburg facility will provide production capacity to support clinical trials in the U.S. and complement BioNTech's existing cell therapy manufacturing facility in Germany.\nFinancial terms were not disclosed.\nKite's new manufacturing facility in Frederick, MD, for commercial production of CAR T-cell therapy is not part of the purchase agreement.\nPrice Action: BNTX shares are up 0.86% at $233.46 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"BNTX":0.9,"GILD":0.9}},"isVote":1,"tweetType":1,"viewCount":2358,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/171169659"}
精彩评论